CURE bleeding criteria: Difference between revisions
No edit summary |
No edit summary |
||
Line 25: | Line 25: | ||
{{Reflist}} | {{Reflist}} | ||
<br> | <br> | ||
{{SIB}} | {{SIB}} |
Revision as of 20:25, 17 June 2011
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
CURE Clinical Trials:
[[The Clopidogrel In Unstable Angina To Prevent Recurrent Events Trial
Clopidogrel In Unstable Angina To Prevent Recurrent Ischemic Events[1]
“ |
Life-threatening (fatal, intracranial, requiring surgical intervention, results in substantial hypotension requiring the use of intravenous inotropic agents) Hemoglobin decrease ≥5 g/dL or required ≥4 U of blood Other major bleeding Transfusion of 2–3 U, intraocular
Led to discontinuation of study drug |
” |
References
- ↑ Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, Yusuf S (2006). "Adverse impact of bleeding on prognosis in patients with acute coronary syndromes". Circulation. 114 (8): 774–82. doi:10.1161/CIRCULATIONAHA.106.612812. PMID 16908769.
bg:Кръвоизлив bs:Krvarenje ca:Hemorràgia cs:Krvácení de:Blutung eu:Odoljario it:Emorragia he:דימום la:Haemorrhagia lt:Kraujavimas nl:Versterkte bloedingsneiging qu:Yawar apariy sv:Blödning